Results 151 to 160 of about 59,797 (283)

Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion

Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley   +1 more source

Long‐Duration Response to Levodopa in the PPMI‐Cohort

Movement Disorders, EarlyView.
Abstract Background Treatment of Parkinson's disease (PD) with levodopa results in a sustained reduction of symptoms. Although the plasma half‐life of levodopa is short, it elicits a lasting effect, the long‐duration levodopa response (LDR). A decrease in LDR as PD progresses has been linked to motor complications, but long‐term data on the LDR and its
Nils Schnalke, Tim Feige, Tom Hähnel, Björn Falkenburger   +3 more
wiley   +1 more source

Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: predictors of response. [PDF]

Front Endocrinol (Lausanne)
Mele C, Zavattaro M, Pitino R, Romanisio M, Ferrero A, Sturnia S, Catenazzi S, Rosmini F, Baldi S, Marzullo P, Aimaretti G, Prodam F, Caputo M.   +12 more
europepmc   +1 more source

Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein. [PDF]

Bioorg Med Chem, 2023
Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D, Antonio T, Reith M, Dutta AK.   +8 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson's Disease in Japan

Background: Dopamine agonists such as bromocriptine or pergolide are often used in Japan to treat Parkinson's disease. Dopamine agonists are relatively expensive drugs; economic evaluations are required.
Kenji Hira, Takuro Shimbo, Tsuguya Fukui, Manabu Takemura   +3 more
core  

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham‐Controlled Trial

Movement Disorders, EarlyView.
Abstract Background Ultrasound‐based neuromodulation, capable of reaching deep brain areas with high precision, represents cutting‐edge technology in non‐invasive brain stimulation and is investigated as a novel treatment for neurological and psychiatric disorders, including Parkinson's disease (PD).
Eva Matt, Nina Plischek, Michael Mitterwallner, Sonja Radjenovic, Alexandra Weber, Alina Domitner, Gregor Dörl, Anna Zettl, Sarah Osou, Anna Leitgeb, Agnes Santer, Viktoria Winkler, Julia Mandelburger, Heidemarie Zach, Roland Beisteiner   +14 more
wiley   +1 more source

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. [PDF]

Chin Neurosurg J, 2022
Cai X, Zhu J, Yang J, Tang C, Cong Z, Ma C.   +5 more
europepmc   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source

A Comparison of Short and Long-Term Acting Dopamine Agonists in the Treatment of Parkinson's Disease with Respect to the Side Effects of Impulse Control Disorder. [PDF]

J Clin Pract Res
Oruc HG, Yildiz BT.
europepmc   +1 more source

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. [PDF]

Front Endocrinol (Lausanne), 2021
Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB.   +5 more
europepmc   +1 more source